Wientjes
Hendrikus Theodorus Gerardus Wientjes, Millingen A/d Rijn NL
Patent application number | Description | Published |
---|---|---|
20110120328 | PRINTING MODULE FOR USE IN AN OFFSET PRINTING APPARATUS AND OFFSET PRINTING APPARATUS PROVIDED WITH SUCH A PRINTING MODULE - A printing module for use in an offset printing apparatus, wherein the printing module is provided with an offset plate cylinder provided with an image to be transferred onto a substrate, wherein the printing module is further provided with an ink system for applying ink onto the offset plate cylinder, at least onto the image provided thereon, and with an impression cylinder, wherein the impression cylinder is arranged, at least in use, to hold the substrate passing between the cylinders against the offset plate cylinder to transfer the image from the offset plate cylinder directly onto the substrate. The invention further relates to an offset printing apparatus provided with such a printing module. | 05-26-2011 |
M. Guillaume Wientjes, Columbus, OH US
Patent application number | Description | Published |
---|---|---|
20110142794 | Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy - A method for determining a therapeutically effective amount of suramin for administering to a patient, who is to receive a cytotoxic agent, which comprises the steps of determining the circulating suramin concentration in the patient; administering suramin, if required, to establish a low circulating concentration of suramin in the patient of below about 200 μM; and administering the chemotherapeutic agent to the patient when the low circulating concentration of suramin is present in the patient. Conveniently a nomogram can be constructed for use in clinical settings with the suramin. | 06-16-2011 |
M. Guillaume Wientjes, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20120225115 | Methods and Compositions for Improved Deliver, Expression or Activity of RNA Interference Agents - The present disclosure provides methods and compositions for enhanced delivery of siRNA or miRNA, into the interior of multilayered tissues, and into the cytoplasm or nucleus of cells of a tissue. Such methods and compositions yield tumor-selective and intracellular delivery of RNAi agents and allow for RNAi-mediated activity such as knock-down of the target genes and associated products. The current disclosure further provides methods and compositions for improving the intracellular bioavailability of nucleotide agents. | 09-06-2012 |